Key result
Tissue factor pathway inhibitor shows therapeutic promise in experimental septic shock and thrombosis models.
Answers are grounded in this paper and cite their sources.
Tissue factor pathway inhibitor is established as an important coagulation inhibitor. The knowledge of the relationship between the structure and function of the tissue factor pathway inhibitor molecule has been widely expanded, especially with regard to its interaction with heparin. Perhaps the most important and promising new studies have investigated the possibility, of using tissue factor pathway inhibitor as a potent drug in the treatment of experimental septic shock and arterial and venous thrombosis.
No takes yet. Share an insight, caveat, or question.
Anne Karin Lindahl (1994) conducted a review in Experimental septic shock and arterial and venous thrombosis. Tissue factor pathway inhibitor was evaluated. Tissue factor pathway inhibitor is being investigated as a potential treatment for experimental septic shock and arterial and venous thrombosis, though no clinical statistics are reported.
Synapse has enriched 10 related papers. Consider them for comparative context: